Janux Therapeutics (JANX) Free Cash Flow (2020 - 2026)
Janux Therapeutics (JANX) reported Free Cash Flow of -$12.6 million for Q1 2026, up 27.51% year-over-year from -$9.9 million in Q1 2025, and up 57.23% quarter-over-quarter from -$29.5 million in Q4 2025.
Janux Therapeutics (JANX) Free Cash Flow (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 7 years of Free Cash Flow data on file, last reported at -$12.6 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$12.6 million, up 27.51% year-over-year; the trailing twelve-month figure through Mar 2026 was -$78.5 million (down 67.97% YoY), and the FY2025 annual result was -$83.3 million, down 88.53% from the prior year.
- Free Cash Flow grew to -$12.6 million in Q1 2026 per JANX's latest filing, from -$29.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$2.0 million in Q3 2024 and troughed at -$29.5 million in Q4 2025.
- A 5-year average of -$14.1 million and a median of -$14.0 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 83.04% in 2024, then plunged 511.46% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$14.0 million in 2022, then surged by 31.25% to -$9.6 million in 2023, then tumbled by 77.47% to -$17.0 million in 2024, then tumbled by 73.01% to -$29.5 million in 2025, then jumped by 57.23% to -$12.6 million in 2026.
- Business Quant data shows JANX's Free Cash Flow at -$12.6 million in Q1 2026, -$29.5 million in Q4 2025, and -$12.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - | -12.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.61 Mn |
| Mar 31, 2026 | -12.61 Mn |
| Dec 31, 2025 | -29.48 Mn |
| Dec 31, 2025 | -29.48 Mn |
| Sep 30, 2025 | -12.11 Mn |
| Sep 30, 2025 | -12.11 Mn |
| Jun 30, 2025 | -24.29 Mn |
| Jun 30, 2025 | -24.29 Mn |
| Mar 31, 2025 | -17.40 Mn |
| Mar 31, 2025 | -17.40 Mn |
| Dec 31, 2024 | -17.04 Mn |
| Dec 31, 2024 | -17.04 Mn |
| Sep 30, 2024 | -1.98 Mn |
| Sep 30, 2024 | -1.98 Mn |
| Jun 30, 2024 | -10.31 Mn |
| Jun 30, 2024 | -10.31 Mn |
| Mar 31, 2024 | -14.84 Mn |
| Mar 31, 2024 | -14.84 Mn |
| Dec 31, 2023 | -9.60 Mn |
| Dec 31, 2023 | -9.60 Mn |